DPP-4 inhibitors and COVID-19 outcomes

The French CORONADO study provides reassuring data about the safety of dipeptidyl peptidase-4 inhibitors in the context of the pandemic, and suggests that prescribing practice need not be changed.

Click here to read our summary.

Share this article

EMPEROR-Preserved: Empagliflozin first therapeutic agent to demonstrate benefits in people with HFpEF

Dapagliflozin approved in the EU for treatment of CKD in people with and without type 2 diabetes

Diabetes before, during and after pregnancy

Early-onset and youth-onset type 2 diabetes: new factsheet

Ramadan and the management of diabetes

Diagnosing and treating hypertension in type 2 diabetes

DPP-4 inhibitors and COVID-19 outcomes

EMPEROR-Preserved: Empagliflozin first therapeutic agent to demonstrate benefits in people with HFpEF

Composite of cardiovascular death or hospitalisation for heart failure significantly reduced by 21% with empagliflozin compared to placebo.

31 Aug 2021

Dapagliflozin approved in the EU for treatment of CKD in people with and without type 2 diabetes

The SGLT2 inhibitor dapagliflozin has been approved in the EU for the treatment of CKD in people with and without type 2 diabetes.

13 Aug 2021

Diabetes before, during and after pregnancy

Diabetes is the most common medical complication of pregnancy and its incidence is increasingly.

14 Jun 2021

For the latest news and articles

Resources

Journals

Useful information